Lipid-Based Pharmaceutical Nanocarriers for Imaging Applications - Nanotechnology for Biomedical Imaging and Diagnostics - page 74

[68] Allen Tm, Haanen C, menenez dEL. pharmacokinetics of long-circulating liposomes.
Adv drug deliv rev 1995; 16 :141-155.
[69] Torchilin VT. How do polymers prolong circulation time of liposomes. J Liposome res
1996; 6 :99-116.
[70] Klibanov AL, maruyama K, Torchilin Vp, Huang L. Amphipathic polyethyleneglycols
effectively prolong the circulation time of liposomes. fEBs Lett 1990; 268 :235-237.
[71] Torchilin Vp. structure and design of polymeric surfactant-based drug delivery systems.
J Control release 2001; 73 :137-172.
[72] gregoriadis g, Neerunjun dE. Control of the rate of hepatic uptake and catabolism of
liposome-entrapped proteins injected into rats. possible therapeutic applications. Eur J
Biochem 1974; 47 :179-185.
[73] senior J, Crawley JC, gregoriadis g. Tissue distribution of liposomes exhibiting long
half-lives in the circulation after intravenous injection. Biochim Biophys Acta 1985;
839 :1-8.
[74] Kirby C, Clarke J, gregoriadis g. Effect of the cholesterol content of small unilamellar
liposomes on their stability in vivo and in vitro. Biochem J 1980; 186 :591-598.
[75] Kirby C, Clarke J, gregoriadis g. Cholesterol content of small unilamellar liposomes
controls phospholipid loss to high density lipoproteins in the presence of serum. fEBs
Lett 1980; 111 :324-328.
[76] senior J, gregoriadis g. stability of small unilamellar liposomes in serum and clearance
from the circulation: the effect of the phospholipid and cholesterol components. Life sci
1982; 30 :2123-2136.
[77] Bosworth mE, Hunt CA. Liposome disposition in vivo ii: dose dependency. J pharm sci
1982; 71 :100-104.
[78] Abra rm, Hunt CA. Liposome disposition in vivo iV: the interaction of sequential doses
of liposomes having different diameters. res Commun Chem pathol pharmacol
1982; 36 :17-31.
[79] Beaumier pL, Hwang KJ, slattery JT. Effect of liposome dose on the elimination of
small unilamellar sphingomyelin/cholesterol vesicles from the circulation. res Commun
Chem pathol pharmacol 1983; 39 :277-289.
[80] goins B, Klipper r, rudolph As, phillips WT. use of technetium-99m-liposomes in
tumor imaging. J Nucl med 1994; 35 :1491-1498.
[81] phillips TW, goins B. Targeted delivery of imaging agents by liposomes. in: Torchilin
Vp, editor. Handbook of Targeted Delivery of Imaging Agents . Boca raton: CrC press;
1995. p 149-176.
[82] maeda H, Wu J, sawa T, matsumura Y, Hori K. Tumor vascular permeability and the Epr
effect in macromolecular therapeutics: a review. J Control release 2000; 65 :271-284.
[83] maeda H. The enhanced permeability and retention (Epr) effect in tumor vasculature:
the key role of tumor-selective macromolecular drug targeting. Adv Enzyme regul
2001; 41 :189-207.
[84] gabizon A, price dC, Huberty J, Bresalier rs, papahadjopoulos d. Effect of liposome
composition and other factors on the targeting of liposomes to experimental tumors:
biodistribution and imaging studies. Cancer res 1990; 50 :6371-6378.
[85] Harrington KJ, rowlinson-Busza g, syrigos KN, uster ps, Abra rm, stewart Js.
Biodistribution and pharmacokinetics of 111in-dTpA-labelled pegylated liposomes in a
human tumour xenograft model: implications for novel targeting strategies. Br J Cancer
2000; 83 :232-238.